AIM: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting.
MATERIALS & METHODS: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n=233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods.
RESULTS: Most patients (67.8%) were male. 44.6% had Child-Pugh A and 39.1% Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS was 85.1% and 64.9%, respectively; landmark OS was 91.8% and 72.6%, respectively.
CONCLUSION: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
